The InGen BioSciences Group, a developer and marketer of advanced in vitro diagnostic kits for clinical use, announced that it has appointed Dr. Isabelle Buckle as CEO.
Dr. Buckle will have executive responsibilities for the Group’s two subsidiaries: InGen, a leading supplier of a large selection of high-performing reagents combined with platform analysis to roughly 750 customers in Europe; and InGen BioSciences, the Group’s R&D facility focused on bringing innovative tests to market that are minimally invasive, fast, cost-effective, and clinically relevant. The Group’s sales reached EUR 20 million in 2009, which is significant for an early-stage biotech company.
“Isabelle has excellent educational credentials and an outstanding professional track record,” said Jean-Pierre Hermet, chairman of the InGen BioSciences Group. “We have great trust in her ability to achieve our goal of transforming the InGen BioSciences Group into a European IVD leader.”
Dr. Isabelle Buckle (49) joins the InGen BioSciences Group from Applied Biosystems, now part of the global technology tools company Life Technologies, where she was business director for Global Strategic Accounts, Worldwide for five years. She was responsible for revenue growth and development of Applied Biosystem’s business relationships with global pharmaceutical accounts. Before that, Dr. Buckle worked for six years with Ciphergen Biosystems, a developer and marketer of protein chip systems, first as regional director for Southern Europe, Belgium and Switzerland. There, she set up the Paris office and successfully launched a new cutting edge technology in proteomics. She then headed Business Development Diagnostic Europe, where she was responsible for collaborating with leading clinical institutions to leverage the scientific and clinical know-how of world experts on a variety of disease related topics in translational medicine. Prior to Ciphergen Biosystems, Dr Buckle worked for nine years at Amersham Pharmacia Biotech (now part of GE). She held in succession a number of positions with increasing responsibility, first as a field specialist, rising to product support manager, and then progressing to sales director for Academic and Clinical Research in France. She then became European business director for Lab Separation. Dr. Buckle holds Masters and BSc degrees in biochemistry and received her PhD in microbiology from the University of Paris VII for a thesis carried out in the Pasteur Institute.
“I am delighted to be working in a dynamic company with leading professionals focused on the fields of proteomics and the synthesis of new recombinant antigens. I see many opportunities that will both increase our distribution panel and continue to supply our R&D funnel with new products that contribute to clinical and diagnostic applications,” said Dr. Isabelle Buckle, CEO of the InGen BioSciences Group.
Since its founding in 2005, the InGen BioSciences Group has experienced 19 percent compound growth (CAGR). The group’s aim is to provide orthopedic surgeons, infectious disease specialists and other medical professionals with easy to use tools for non-invasive detection of infections in pre- and post-operated implants. Its first proprietary product, BJI InoPlex, was launched earlier this year. The Group plans to develop serology and immunodiagnostics products to add to its current portfolio. Dr. Buckle sees significant potential in these products as they respond to present and future needs in the rapidly evolving field of diagnostics in human healthcare.
Date: December 16, 2010
Source: InGen BioSciences Group
